179 related articles for article (PubMed ID: 35110641)
1. Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan.
Naito T; Mori H; Fujibayashi K; Fukushima S; Yuda M; Fukui N; Tsukamoto S; Suzuki M; Goto-Hirano K; Kuwatsuru R
Sci Rep; 2022 Feb; 12(1):1732. PubMed ID: 35110641
[TBL] [Abstract][Full Text] [Related]
2. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
3. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.
Ruzicka DJ; Kamakura M; Kuroishi N; Oshima N; Yamatani M; Yi J; Crawford B; Tsukada K; Oka S
PLoS One; 2022; 17(6):e0269779. PubMed ID: 35700215
[TBL] [Abstract][Full Text] [Related]
5. Effect of Switching Antiretroviral Treatment Regimen in Patients With Drug-Resistant HIV-1 Infection: Retrospective Observational Cohort Study.
Li Y; Wang Q; Liang S; Feng C; Yang H; Yu H; Yuan D; Yang S
JMIR Public Health Surveill; 2022 Jun; 8(6):e33429. PubMed ID: 35749212
[TBL] [Abstract][Full Text] [Related]
6. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer.
Torres HA; Rallapalli V; Saxena A; Granwehr BP; Viola GM; Ariza-Heredia E; Adachi JA; Chemaly RF; Marfatia R; Jiang Y; Mahale P; Kyvernitakis A; Fanale MA; Mulanovich V
Clin Microbiol Infect; 2014 Oct; 20(10):O672-9. PubMed ID: 24529214
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study.
Harding BN; Whitney BM; Nance RM; Crane HM; Burkholder G; Moore RD; Mathews WC; Eron JJ; Hunt PW; Volberding P; Rodriguez B; Mayer K; Saag MS; Kitahata MM; Heckbert SR; Delaney JAC
BMJ Open; 2020 Mar; 10(3):e031487. PubMed ID: 32198297
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States.
Korsnes JS; Goodwin BB; Murray M; Candrilli SD
Ann Pharmacother; 2016 Dec; 50(12):989-1000. PubMed ID: 27439947
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs in patients with HIV-1 who switched first-line antiretroviral therapy.
Mao J; Johnson MP; McPheeters JT; Prajapati G; Beyer AP
Curr Med Res Opin; 2019 Nov; 35(11):1945-1953. PubMed ID: 31311342
[No Abstract] [Full Text] [Related]
12. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
15. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
16. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
18. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
[TBL] [Abstract][Full Text] [Related]
19. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
20. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
Torti C; d'Arminio-Monforte A; Pozniak AL; Lapadula G; Cologni G; Antinori A; De Luca A; Mussini C; Castagna A; Cicconi P; Minoli L; Costantini A; Carosi G; Liang H; Cesana BM;
BMC Infect Dis; 2011 Jan; 11():23. PubMed ID: 21266068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
